Results 111 to 120 of about 102,247,329 (239)

A History of the Development of Alternatives to Animals in Research and Testing

Growing public interest in animal welfare issues in recent decades has prompted increased attention to the efforts to develop alternative, nonanimal methods for use in biomedical research and product testing.
Parascandola, John
core  

Prediction of Skin Sensitizers using Alternative Methods to Animal Experimentation.

, 2014
Regulatory frameworks within the European Union demand that chemical substances are investigated for their ability to induce sensitization, an adverse health effect caused by the human immune system in response to chemical exposure.
Johansson, Henrik, Lindstedt, Malin, Malin Lindstedt, Henrik Johansson, Johansson, Henrik,, Lindstedt, Malin,, Lund University.   +6 more
core   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Development of Biocompatibility and Embryotoxicity Testing Methods at NSU as an Alternative to Animal Experimentation

, 2006
Every year in the United States, millions of animals including monkey\u27s, rats, mice, rabbits, cats, and dogs suffer experimentation to test the biocompatibility of products before they are used on humans.
Coffman, Jonathan, Murray, Peter
core   +1 more source

Alternative approach to animal testing and cell cultures, according to European laws

ALTEX: Alternatives to Animal Experimentation, 2017
Chiara Scanarotti, Costanza Rovida, Susanna Penco, Stefania Vernazza, Sara Tirendi, Rosagemma Ciliberti, Anna Maria Bassi   +6 more
doaj   +1 more source

Revolutionizing developmental neurotoxicity testing – A journey from animal models to advanced in vitro systems

ALTEX: Alternatives to Animal Experimentation
Developmental neurotoxicity (DNT) testing has seen enormous progress over the last two decades. Preceding even the publication of the animal-based OECD test guideline for DNT testing in 2007, a series of non-animal technology workshops and conferences ...
Lena Smirnova, Helena T. Hogberg, Marcel Leist, Thomas Hartung   +3 more
doaj   +1 more source

Dissemination strategies: how do they influence the uptake of the new Three Rs methods across laboratories and other boundaries? A report of a workshop held by the European Partnership for Alternative Approaches to Animal Testing (EPAA) Working Group 3

, 2008
The European Partnership for Alternative Approaches to Animal Testing (EPAA; 1) organised a workshop in October 2007, to review whether dissemination plays a role in the successful uptake of new Three Rs methods.
Connolly, P., Lacerda, A., Hermans, H., Basketter, D., Spielmann, H., Elvig-Jorgensen, S. G., Robinson, S., Hoffmeister, A., Bussi, R., Coenen, J., Watson, T., Valk, J.van der, Torok, M., Linge, J. P.   +13 more
core  

The Animal Welfare Act at Fifty: Problems and Possibilities in Animal Testing Regulation [PDF]

, 2016
I. Introduction II. Background of the Animal Welfare Act ... A. Enactment and Evolution ... B. Early Amendments ... C. Improved Standards for Laboratory Animals Act of 1985 ... D. Institutional Animal Care and Use Committees ... E.
Lee, Courtney G.
core  

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source